Imatinib Mesylate in Treating Patients With Recurrent Meningioma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Adult Grade I MeningiomaAdult Grade II MeningiomaAdult Grade III MeningiomaAdult Meningeal HemangiopericytomaAdult MeningiomaRecurrent Adult Brain Tumor
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (7)

10021

Memorial Sloan-Kettering Cancer Center, New York

20814

National Cancer Institute Neuro-Oncology Branch, Bethesda

53792

University of Wisconsin, Madison

75235

University of Texas Southwestern Medical Center, Dallas

90095

University of California Los Angeles, Los Angeles

94115

University of California San Francisco, San Francisco

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00045734 - Imatinib Mesylate in Treating Patients With Recurrent Meningioma | Biotech Hunter | Biotech Hunter